Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation

Annals of Hematology

Volumn 90, Issue 12, 2011, Pages 1409-1418

  Kim, Ji Won ^a   Kim, Byung Su ^a   Bang, Soo Mee ^a   Kim, Inho ^a,b   Kim, Dong Hwan ^c   Kim, Won Seog ^c   Yang, Deok Hwan ^d   Lee, Je Jung ^d   Lee, Je Hwan ^e   Kim, Jin Seok ^f   Sohn, Sang Kyun ^g   Yhim, Ho Young ^h   Kwak, Jae Yong ^h   Yoon, Sung Soo ^a,b   Lee, Jong Seok ^a   Park, Seonyang ^a,b   Kim, Byoung Kook ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Chonnam National University Medical School   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g Kyungpook National University School of Medicine   (South Korea)

^h Chonbuk National University Medical School   (South Korea)

Author keywords

Albumin; Donor lymphocyte infusion; Non Hodgkin lymphoma; Performance status; Stem cell transplantation

Indexed keywords

ALBUMIN; ALEMTUZUMAB; BUSULFAN; CARBOPLATIN; CARMUSTINE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; NIMUSTINE; TACROLIMUS; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALBUMIN BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CD34 SELECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; EVENT FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LENGTH OF STAY; LIVER TOXICITY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; NEPHROTOXICITY; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SURVIVAL TIME; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; KOREA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84355161831     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1227-y     Document Type: Article

References (21)

1. T Philip C Guglielmi A Hagenbeek R Somers H Van der Lelie D Bron P Sonneveld C Gisselbrecht JY Cahn JL Harousseau, et al. 1995 Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 333 23 1540 1545 7477169 10.1056/NEJM199512073332305 1:STN:280:DyaK28%2FmslCgtQ%3D%3D
2. C Haioun E Lepage C Gisselbrecht G Salles B Coiffier P Brice A Bosly P Morel C Nouvel H Tilly P Lederlin C Sebban J Briere P Gaulard F Reyes 2000 Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol-a groupe d'Etude des lymphomes de l'Adulte study J Clin Oncol 18 16 3025 3030 10944137 1:STN:280:DC%2BD3cvivFCkug%3D%3D (Pubitemid 30644128)
3. N Milpied E Deconinck F Gaillard V Delwail C Foussard C Berthou R Gressin V Lucas P Colombat JL Harousseau 2004 Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support N Engl J Med 350 13 1287 1295 10.1056/NEJMoa031770 15044639 10.1056/NEJMoa031770 1:CAS:528:DC%2BD2cXisFyiur4%3D (Pubitemid 38375363)
4. J Shamash SM Lee JA Radford AZ Rohatiner J Chang GR Morgenstern JH Scarffe DP Deakin TA Lister 2000 Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study Ann Oncol 11 6 715 719 10942061 10.1023/A:1008362700606 1:STN:280:DC%2BD3MzgsVejsQ%3D%3D
5. KW van Besien M de Lima SA Giralt DF Moore Jr IF Khouri G Rondon R Mehra BS Andersson C Dyer K Cleary D Przepiorka JL Gajewski RE Champlin 1997 Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect Bone Marrow Transplant 19 10 977 982 10.1038/sj.bmt.1700781 9169641 10.1038/sj.bmt.1700781 (Pubitemid 27232173)
6. M de Lima KW van Besien SA Giralt IF Khouri R Mehra BS Andersson D Przepiorka JL Gajewski M Korbling RE Champlin 1997 Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma Bone Marrow Transplant 19 2 121 127 10.1038/sj.bmt.1700614 9116608 10.1038/sj.bmt.1700614 (Pubitemid 27068247)
7. MP Escalon RE Champlin RM Saliba SA Acholonu C Hosing L Fayad S Giralt NT Ueno F Maadani B Pro M Donato P McLaughlin IF Khouri 2004 Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation J Clin Oncol 22 12 2419 2423 10.1200/JCO.2004.09.092 15197204 10.1200/JCO.2004.09.092 (Pubitemid 41115399)
8. CO Freytes FR Loberiza JD Rizzo A Bashey CN Bredeson MS Cairo RP Gale MM Horowitz TR Klumpp R Martino PL McCarthy A Molina S Pavlovsky AL Pecora DS Serna T Tsai MJ Zhang JM Vose HM Lazarus K van Besien 2004 Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry Blood 104 12 3797 3803 10.1182/blood-2004-01-0231 15280203 10.1182/blood-2004-01-0231 1:CAS:528:DC%2BD2cXhtVGltb3E (Pubitemid 39564460)
9. BD Cheson SJ Horning B Coiffier MA Shipp RI Fisher JM Connors TA Lister J Vose A Grillo-Lopez A Hagenbeek F Cabanillas D Klippensten W Hiddemann R Castellino NL Harris JO Armitage W Carter R Hoppe GP Canellos 1999 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 4 1244 10561185 1:STN:280:DC%2BD3c%2FivF2itg%3D%3D
10. BD Cheson B Pfistner ME Juweid RD Gascoyne L Specht SJ Horning B Coiffier RI Fisher A Hagenbeek E Zucca ST Rosen S Stroobants TA Lister RT Hoppe M Dreyling K Tobinai JM Vose JM Connors M Federico V Diehl 2007 Revised response criteria for malignant lymphoma J Clin Oncol 25 5 579 586 10.1200/JCO.2006.09. 2403 17242396 10.1200/JCO.2006.09.2403 (Pubitemid 350002966)
11. D Przepiorka D Weisdorf P Martin HG Klingemann P Beatty J Hows ED Thomas 1995 1994 consensus conference on acute GVHD grading Bone Marrow Transplant 15 6 825 828 7581076 1:STN:280:DyaK28%2Fot1Ojtw%3D%3D
12. SW Kim TE Tanimoto N Hirabayashi S Goto M Kami S Yoshioka T Uchida K Kishi Y Tanaka A Kohno M Kasai M Higuchi S Mori T Fukuda K Izutsu H Sao T Ishikawa T Ichinohe K Takeuchi K Tajima R Tanosaki M Harada S Taniguchi K Tobinai T Hotta Y Takaue 2006 Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan Blood 108 1 382 389 10.1182/blood-2005-02-0596 16522821 10.1182/blood-2005-02-0596 1:CAS:528:DC%2BD28XmsVOlsro%3D (Pubitemid 43990653)
13. KS Peggs S Mackinnon DC Linch 2005 The role of allogeneic transplantation in non-Hodgkin's lymphoma Br J Haematol 128 2 153 168 10.1111/j.1365-2141.2004. 05251.x 15638849 10.1111/j.1365-2141.2004.05251.x
14. N Schmitz P Dreger B Glass A Sureda 2007 Allogeneic transplantation in lymphoma: current status Haematologica 92 11 1533 1548 10.3324/haematol.11185 18024402 10.3324/haematol.11185 (Pubitemid 350144129)
15. A Sureda S Robinson C Canals AM Carella MA Boogaerts D Caballero AE Hunter L Kanz S Slavin JJ Cornelissen M Gramatzki D Niederwieser NH Russell N Schmitz 2008 Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J Clin Oncol 26 3 455 462 10.1200/JCO.2007.13. 2415 18086796 10.1200/JCO.2007.13.2415 1:CAS:528:DC%2BD1cXitVGnurk%3D (Pubitemid 351171699)
16. E Velasco LC Thuler CA Martins LM Dias VM Goncalves 1998 Risk factors for bloodstream infections at a cancer center Eur J Clin Microbiol Infect Dis 17 8 587 590 9796661 10.1007/s100960050137 1:STN:280:DyaK1M%2FhtVKrtw%3D%3D (Pubitemid 28464367)
17. E Velasco RD Portugal JI Salluh 2009 A simple score to predict early death in adult cancer patients with bloodstream infections J Infect 59 5 332 336 10.1016/j.jinf.2009.08.009 19706307 10.1016/j.jinf.2009.08.009
18. K Izutsu Y Kanda H Ohno H Sao H Ogawa Y Miyazaki K Kawa Y Kodera S Kato Y Morishima H Hirai 2004 Unrelated bone marrow transplantation for non-Hodgkin lymphoma: a study from the Japan Marrow Donor Program Blood 103 5 1955 1960 10.1182/blood-2003-03-0937 14604976 10.1182/blood-2003-03-0937 1:CAS:528:DC%2BD2cXhvVOhtL4%3D (Pubitemid 38268998)
19. AJ Peniket MC Ruiz de Elvira G Taghipour C Cordonnier E Gluckman T de Witte G Santini D Blaise H Greinix A Ferrant J Cornelissen N Schmitz AH Goldstone 2003 An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation Bone Marrow Transplant 31 8 667 678 10.1038/sj.bmt.1703891 12692607 10.1038/sj.bmt.1703891 1:STN:280:DC%2BD3s7ntlekuw%3D%3D (Pubitemid 36553477)
20. CM Mandigers LF Verdonck JP Meijerink AW Dekker AV Schattenberg JM Raemaekers 2003 Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation Bone Marrow Transplant 32 12 1159 1163 10.1038/sj.bmt.1704290 14647270 10.1038/sj.bmt.1704290 1:STN:280:DC%2BD3srmsFKrsA%3D%3D (Pubitemid 38072329)
21. DI Marks R Lush J Cavenagh DW Milligan S Schey A Parker FJ Clark L Hunt J Yin S Fuller E Vandenberghe J Marsh T Littlewood GM Smith D Culligan A Hunter R Chopra A Davies K Towlson CD Williams 2002 The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation Blood 100 9 3108 3114 10.1182/blood-2002-02-0506 12384406 10.1182/blood-2002-02-0506 1:CAS:528:DC%2BD38XosVSis7k%3D (Pubitemid 35217056)